24 June 2021
2021 Webinar | Why you should consider controlling your potentially mutagenic impurities outside the lab
We were delighted to welcome external speaker, Dr. Andrew Teasdale to present at this event - Andy is currently the chair of AstraZeneca’s Impurity Advisory Board and has a wealth of knowledge developed over the last 20 years of working within the pharmaceutical industry. He is a leading AstraZeneca expert for a number of key impurity areas, including mutagenic impurities (MIs).
Andy’s presentation covered the following topics:
- The challenges of controlling potentially mutagenic impurities
- How using the paper-based approach can reduce the time and effort associated with these challenges
- AstraZeneca’s experience of how Mirabilis can help further
- Top tips for applying control option 4.
A recording of Andy's presentation is available from this page.
Following Andy's presentation, Raeesah Saddiq, Business Development Executive within Applied Sciences function at Lhasa Limited, provided an overview of Mirabilis. To arrange a Mirabilis demonstration for your organisation, please get in touch.
Headline Event (shown first above featured)